Multi-center experience with novel transplant conditioning regimens that incorporate 90Y ibritumomab tiuxetan (Zevalin®) Radioimmunotherapy (RIT) for autologous and allogeneic stem cell transplantation in patients with poor-risk B-cell non-hodgkin's lymphoma (NHL):: Targeted intensification and elimination of total body irradiation

被引：0
|
作者：
Molina, A
Nademanee, A
Winter, JN
Fung, HC
Inwards, DJ
Multani, P
Khouri, I
Raubitschek, A
White, CA
机构：
[1] IDEC Pharm, Med Affairs, San Diego, CA USA
[2] City Hope Canc Ctr, Dept Hematol & Bone Marrow Transplantat, Duarte, CA USA
[3] Northwestern Univ, Div Hematol Oncol, Chicago, IL 60611 USA
[4] Mayo Clin & Mayo Fdn, Sch Med, Rochester, MN USA
[5] Univ Texas, MD Anderson Canc Ctr, Houston, TX 77030 USA
来源：
JOURNAL OF IMMUNOTHERAPY | 2003年 / 26卷 / 06期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：S48 / S48
页数：1
相关论文
共 40 条
  • [31] 90Y-Ibritumomab tiuxetan (Zevalin®) in combination with high-dose therapy (HDT) followed by autologous stem cell transplant (ASCT) may improve survival in patients with poor-risk follicular lymphoma (FL) and diffuse large B-Cell lymphoma (DLBCL):: Results of a retrospective comparative analysis.
    Nademanee, Auayporn-P.
    Krishnan, Amrita
    Tsai, Nicole
    Palmer, Joycelynne
    Molina, Arturo
    Fung, Henry C.
    Yamauchi, David
    Kogut, Neil Martin
    Forman, Stephen J.
    Raubitschek, Andrew
    BLOOD, 2006, 108 (11) : 102A - 102A
  • [32] A phase 1/2 trial of high-dose yttrium-90-ibritumomab tiuxetan in combination with high-dose etoposide and cyclophosphamide followed by autologous stem cell transplantation in patients with poor-risk or relapsed non-Hodgkin lymphoma
    Nademanee, A
    Forman, S
    Molina, A
    Fung, H
    Smith, D
    Dagis, A
    Kwok, C
    Yamauchi, D
    Anderson, AL
    Falk, P
    Krishnan, A
    Kirschbaum, M
    Kogut, N
    Nakamura, R
    O'Donnell, M
    Parker, P
    Popplewell, L
    Pullarkat, V
    Rodriguez, R
    Sahebi, F
    Smith, E
    Snyder, D
    Stein, A
    Spielberger, R
    Zain, J
    White, C
    Raubitschek, A
    BLOOD, 2005, 106 (08) : 2896 - 2902
  • [33] Ibritumomab tiuxetan (Zevalin) followed by high-dose chemotherapy and autologous stem-cell transplantation results in improved survival of patients with chemo-refractory non-Hodgkin's lymphoma expected to have poor outcome with standard pre-transplant conditioning.
    Shimoni, Avichai
    Zwass, Tsila
    Oksman, Yaacov
    Hardan, Izhar
    Shem-Tov, Noga
    Yerushalmi, Ronit
    Avigdor, Abraham
    Ben-Bassat, Isaac
    Nagler, Arnon
    BLOOD, 2006, 108 (11) : 869A - 869A
  • [34] The safety and efficacy of standard-dose 90Y ibritumomab tiuxetan combined with high-dose BEAM and autologous stem-cell transplantation in patients, including those over 60 years, with non-Hodgkin's lymphoma
    Krishnan, A
    Nademanee, A
    Forman, SJ
    Fung, H
    Molina, A
    Yamauchi, D
    Spielberger, RT
    Kogut, NM
    Raubitschek, A
    INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2005, 63 (02): : S419 - S420
  • [35] 90Y ibritumomab tiuxetan (Y2B8, Zevalin®) radioimmunotherap (RIT) is highly effective for relapsed or refractory indolent B-cell non-Hodgkin's lyrnphoma (B-NHL) pretreated with rituximab-containing chemotherapy (R-chemo):: Japanese multicenter phase II study.
    Ogura, Michinori
    Morishima, Yasuo
    Watanabe, Takashi
    Hotta, Tomomitsu
    Ishizawa, Kennichi
    Itoh, Kuniaki
    Okamoto, Shinichiro
    Taniwaki, Masafumi
    Endo, Kengo
    Tobinai, Kensei
    BLOOD, 2006, 108 (11) : 783A - 784A
  • [36] Can elimination of total body irradiation (TBI) in conditioning regimens for autologous stem cell transplantation (SCT) in patients with Hodgkin and non-Hodgkin lymphoma decrease the risk of secondary AML/MDS(sAML/MDS)? A retrospective case-control study at the University of Nebraska Medical Center.
    Maness, LJ
    Loberiza, FR
    Sanger, W
    DeVetten, MP
    Bierman, P
    Bociek, G
    Armitage, JO
    Vose, JM
    BLOOD, 2005, 106 (11) : 201A - 202A
  • [37] 90yttrium Ibritumomab Tiuxetan-BEAM Followed by Autologous Stem Cell Transplantation Significantly Improves Overall Survival After Rituximab Containing Induction Therapy in Patients with High-Risk Aggressive B Cell Non-Hodgkin's Lymphoma
    Wondergem, Marielle
    de Rooij, Madelon
    Zijlstra, Josee
    Visser, Otto J.
    Ossenkoppele, Gert
    Huijgens, Peter C.
    BLOOD, 2011, 118 (21) : 1328 - 1328
  • [38] A new preparative regimen for older patients with aggressive CD 20-positive B-cell lymphoma utilizing standard-dose yttrium-90 ibritumomab tiuxetan (Zevalin®) radioimmunotherapy (RIT) combined with high-dose BEAM followed by autologous hematopoietic cell transplantation (AHCT):: Targeted intensification without increased transplant-related toxicity.
    Fung, HC
    Forman, SJ
    Nademanee, A
    Molina, A
    Yamauchi, D
    Speilberger, R
    Kogut, N
    Sahebi, F
    Parker, P
    Rodriguez, R
    Krishnan, A
    Popplewell, L
    Wong, J
    Raubitschek, A
    BLOOD, 2003, 102 (11) : 248A - 248A
  • [39] TARGETED INTENSIFICATION BY A PREPARATIVE REGIMEN FOR PATIENTS WITH DIFFUSE LARGE B-CELL LYMPHOMA (DLBCL) UTILIZING STANDARD-DOSE YTTRIUM-90 IBRITUMOMAB TIUXETAN RADIOIMMUNOTHERAPY (RIT) COMBINED WITH BEAM FOLLOWED BY AUTOLOGOUS STEM CELL TRANSPLANTATION (ASCT). GROUPE D'ETUDE DES LYMPHOMES DE L'ADULTE (GELA) STUDY Z-BEAM 2
    Fruchart, C.
    Tilly, H.
    Morschhauser, F.
    Sebban, C.
    Salles, G.
    Ferme, C.
    Van Hoof, A.
    Bordessoule, D.
    Bouabdallah, R.
    Delmer, A.
    Van Den Neste, E.
    Laurent, G.
    Picquenot, J. M.
    Fournier, M.
    Gisselbrecht, C.
    ANNALS OF ONCOLOGY, 2011, 22 : 169 - 169
  • [40] Augmented preparative regimens using total body irradiation or BCNU prior to autologous stem cell transplant (AuSCT) are well-tolerated and yield substantial rates of progression-free survival in patients with poor risk Hodgkin lymphoma (HL) or diffuse large B-cell lymphoma (DLBCL).
    Ritchie, DS
    Seymour, JF
    Thompson, S
    McManus, M
    Prince, M
    BLOOD, 2005, 106 (11) : 463B - 463B
1234